Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2017

22.03.2017 | Original Article

Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden

verfasst von: Janusch Blautzik, Matthias Brendel, Julia Sauerbeck, Sebastian Kotz, Franziska Scheiwein, Peter Bartenstein, John Seibyl, Axel Rominger, for the Alzheimer’s Disease Neuroimaging Initiative

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Relative quantitative analysis of amyloid plaque burden in Alzheimer’s disease (AD) patients can be reported as standardized uptake value ratio (SUVR) from positron emission tomography (PET). Here, the SUVR is the ratio of the mean amyloid radioligand retention in a composite (COMP) neocortical volume of interest (VOI) to that in a reference VOI, such as the cerebellum, brainstem (BST)/pons, or white matter (WM). Some longitudinal PET investigations show that the rate of amyloid accumulation to follow-up has an inverted U relationship with baseline amyloid SUVR relative to cerebellar or brainstem/pons reference VOIs. The corresponding association with SUVR relative to WM is unknown. To test the possible benefits of WM normalization, we analyzed [18F]-AV45 PET data from 404 subjects in the AD Neuroimaging Initiative (ADNI) database at baseline and 2-year follow-up (144 cognitively normal controls, 225 patients with mild cognitive impairment, and 35 AD patients). Reference regions included subcortical WM as well as conventional cerebellar gray matter (CBL), and BST. We tested associations between each subject’s inter-session change (∆) of SUVR and their baseline SUVR by applying linear, logarithmic, and quadratic regression analyses. Unscaled standardized uptake values (SUVs) were correlated between VOIs at baseline and follow-up, and within VOIs in the longitudinal run. The association between ∆SUVR and baseline SUVR relative to WM reference was best described by an inverted U-shaped function. Correlation analyses demonstrated a high regional and temporal correlation between COMP and WM VOI SUVs. For WM normalization, we confirm that the rate of amyloid accumulation over time follows an inverted U-shaped function of baseline amyloid burden. Reference region selection, however, has substantial effects on SUVR results. This reflects the extent of covariance between SUVs in the COMP VOI and those in the various reference VOIs. We speculate that PET labeling of amyloid deposition within target regions is partially confounded by effects of longitudinal changes of cerebral blood flow (CBF) on tracer delivery. Indeed, CBF may be the leading factor influencing longitudinal SUV changes. We suggest that SUVR relative to WM may be more robust to changes in CBF, and thus fitter for sensitive detection of amyloid accumulation in intervention studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. doi:10.2967/jnumed.111.090340.CrossRefPubMed Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. doi:10.​2967/​jnumed.​111.​090340.CrossRefPubMed
5.
7.
Zurück zum Zitat Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.CrossRefPubMed Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.​1016/​S1474-4422(13)70044-9.CrossRefPubMed
10.
Zurück zum Zitat Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement. 2015;11:975–85. doi:10.1016/j.jalz.2015.05.018.CrossRefPubMed Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement. 2015;11:975–85. doi:10.​1016/​j.​jalz.​2015.​05.​018.CrossRefPubMed
11.
Zurück zum Zitat Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35. doi:10.1016/S1474-4422(11)70077-1.CrossRefPubMed Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35. doi:10.​1016/​S1474-4422(11)70077-1.CrossRefPubMed
12.
Zurück zum Zitat Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126–39. doi:10.1093/brain/aws125.CrossRefPubMed Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126–39. doi:10.​1093/​brain/​aws125.CrossRefPubMed
14.
Zurück zum Zitat Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560–6. doi:10.2967/jnumed.114.149732.CrossRefPubMed Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560–6. doi:10.​2967/​jnumed.​114.​149732.CrossRefPubMed
16.
Zurück zum Zitat Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. doi:10.1002/hbm.10123.CrossRefPubMed Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. doi:10.​1002/​hbm.​10123.CrossRefPubMed
17.
Zurück zum Zitat Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors Second International Symposium on Information Theory; Budapest Akademiai Kiado. 1973:pp. 267–81. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors Second International Symposium on Information Theory; Budapest Akademiai Kiado. 1973:pp. 267–81.
18.
Zurück zum Zitat Cumming P, Xiong G, la Fougere C, Rominger A, Bartenstein P, Buchholz HG, et al. Surrogate markers for cerebral blood flow correlate with [(1)(8)F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum. Synapse. 2013;67:199–203. doi:10.1002/syn.21630.CrossRefPubMed Cumming P, Xiong G, la Fougere C, Rominger A, Bartenstein P, Buchholz HG, et al. Surrogate markers for cerebral blood flow correlate with [(1)(8)F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum. Synapse. 2013;67:199–203. doi:10.​1002/​syn.​21630.CrossRefPubMed
21.
Zurück zum Zitat Alegret M, Cuberas-Borros G, Vinyes-Junque G, Espinosa A, Valero S, Hernandez I, et al. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer’s disease. J Alzheimer’s Dis : JAD. 2012;30:109–20. doi:10.3233/JAD-2012-111850.PubMedPubMedCentral Alegret M, Cuberas-Borros G, Vinyes-Junque G, Espinosa A, Valero S, Hernandez I, et al. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer’s disease. J Alzheimer’s Dis : JAD. 2012;30:109–20. doi:10.​3233/​JAD-2012-111850.PubMedPubMedCentral
22.
Zurück zum Zitat Nishimura T, Hashikawa K, Fukuyama H, Kubota T, Kitamura S, Matsuda H, et al. Decreased cerebral blood flow and prognosis of Alzheimer’s disease: a multicenter HMPAO-SPECT study. Ann Nucl Med. 2007;21:15–23.CrossRefPubMed Nishimura T, Hashikawa K, Fukuyama H, Kubota T, Kitamura S, Matsuda H, et al. Decreased cerebral blood flow and prognosis of Alzheimer’s disease: a multicenter HMPAO-SPECT study. Ann Nucl Med. 2007;21:15–23.CrossRefPubMed
24.
25.
Zurück zum Zitat Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18. doi:10.1007/s00259-014-2728-4.CrossRefPubMed Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014;41:1408–18. doi:10.​1007/​s00259-014-2728-4.CrossRefPubMed
Metadaten
Titel
Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden
verfasst von
Janusch Blautzik
Matthias Brendel
Julia Sauerbeck
Sebastian Kotz
Franziska Scheiwein
Peter Bartenstein
John Seibyl
Axel Rominger
for the Alzheimer’s Disease Neuroimaging Initiative
Publikationsdatum
22.03.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3666-8

Weitere Artikel der Ausgabe 8/2017

European Journal of Nuclear Medicine and Molecular Imaging 8/2017 Zur Ausgabe